Browse Studies — Arctuva

Phase 3

Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Nonfunctional Neuroendocrine Neoplasms (REMAIN Trial)

This is a multicenter, randomized, open-label, phase III study comparing standard of care use of somatostatin analogues (SSAs) to standard of care observation …

Neuroendocrine NeoplasmGastroenteropancreatic Neuroendocrine Neoplasm

Estimated

~$10 – $6,250

Washington University School of MedicineNCT07842172

Phase 1

211At-MABG in Adults With Advanced Neuroendocrine Cancers

Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced b…

PheochromocytomaParagangliomaNeuroendocrine Tumors+3 more

Estimated

~$10 – $6,250

University of PennsylvaniaNCT07661420

Phase 2

A Phase II Study of Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) in Patients With Progressing Metastatic Neuroendocrine Carcinomas (NECs)

This phase IIa trial compares the safety and effect of temozolomide combined with survivin long peptide vaccine (SurVaxM) to temozolomide alone in patients wit…

Digestive System Neuroendocrine NeoplasmLung Neuroendocrine NeoplasmMalignant Solid Neoplasm+1 more

Estimated

~$10 – $7,500

Roswell Park Cancer InstituteNCT06202066

Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms

This is a prospective observational multi-center pilot study of germline testing for participants receiving care at University of California participating loca…

Pancreatic Neuroendocrine Neoplasm

Estimated

~$10 – $675

University of California, San FranciscoNCT05746182